Standard BioTools Inc. (LAB)
USD 1.99
(-10.18%)
USD 1.99
(-10.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 113.48 Million USD | -25.95% |
| 2022 | 153.25 Million USD | 12.0% |
| 2021 | 136.83 Million USD | 1.84% |
| 2020 | 134.36 Million USD | 15.71% |
| 2019 | 116.11 Million USD | 5.74% |
| 2018 | 109.81 Million USD | -0.48% |
| 2017 | 110.34 Million USD | -16.17% |
| 2016 | 131.62 Million USD | 7.69% |
| 2015 | 122.22 Million USD | 6.52% |
| 2014 | 114.74 Million USD | 69.28% |
| 2013 | 67.78 Million USD | 23.07% |
| 2012 | 55.08 Million USD | 21.75% |
| 2011 | 45.24 Million USD | 23.77% |
| 2010 | 36.55 Million USD | 14.36% |
| 2009 | 31.96 Million USD | -12.49% |
| 2008 | 36.52 Million USD | 33.86% |
| 2007 | 27.28 Million USD | 7.9% |
| 2006 | 25.28 Million USD | 0.0% |
| 2001 | 144.72 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 47.55 Million USD | -3.37% |
| 2024 Q1 | 62.92 Million USD | 122.63% |
| 2024 Q2 | 56.89 Million USD | -9.58% |
| 2023 Q2 | 28.78 Million USD | 0.23% |
| 2023 Q1 | 28.71 Million USD | -11.04% |
| 2023 FY | 113.48 Million USD | -25.95% |
| 2023 Q4 | 28.26 Million USD | -1.39% |
| 2023 Q3 | 28.66 Million USD | -0.42% |
| 2022 Q4 | 32.27 Million USD | -15.6% |
| 2022 Q2 | 42.99 Million USD | 8.18% |
| 2022 FY | 153.25 Million USD | 12.0% |
| 2022 Q3 | 38.24 Million USD | -11.03% |
| 2022 Q1 | 39.74 Million USD | 26.15% |
| 2021 FY | 136.83 Million USD | 1.84% |
| 2021 Q1 | 38.36 Million USD | -11.04% |
| 2021 Q2 | 33.68 Million USD | -12.18% |
| 2021 Q3 | 33.28 Million USD | -1.21% |
| 2021 Q4 | 31.5 Million USD | -5.35% |
| 2020 Q4 | 43.12 Million USD | 40.08% |
| 2020 Q1 | 31.39 Million USD | 15.98% |
| 2020 FY | 134.36 Million USD | 15.71% |
| 2020 Q2 | 29.06 Million USD | -7.42% |
| 2020 Q3 | 30.78 Million USD | 5.91% |
| 2019 Q2 | 29.99 Million USD | -3.84% |
| 2019 FY | 116.11 Million USD | 5.74% |
| 2019 Q1 | 31.19 Million USD | 4.23% |
| 2019 Q3 | 27.85 Million USD | -7.15% |
| 2019 Q4 | 27.06 Million USD | -2.82% |
| 2018 Q1 | 26.06 Million USD | 13.21% |
| 2018 FY | 109.81 Million USD | -0.48% |
| 2018 Q2 | 26.37 Million USD | 1.2% |
| 2018 Q3 | 27.45 Million USD | 4.08% |
| 2018 Q4 | 29.92 Million USD | 9.03% |
| 2017 FY | 110.34 Million USD | -16.17% |
| 2017 Q4 | 23.02 Million USD | -17.15% |
| 2017 Q3 | 27.78 Million USD | -2.29% |
| 2017 Q2 | 28.43 Million USD | -8.57% |
| 2017 Q1 | 31.1 Million USD | -1.4% |
| 2016 FY | 131.62 Million USD | 7.69% |
| 2016 Q1 | 35.88 Million USD | 12.76% |
| 2016 Q2 | 33.82 Million USD | -5.75% |
| 2016 Q3 | 30.37 Million USD | -10.19% |
| 2016 Q4 | 31.54 Million USD | 3.84% |
| 2015 Q4 | 31.82 Million USD | 9.73% |
| 2015 Q1 | 30.08 Million USD | -1.54% |
| 2015 Q2 | 31.31 Million USD | 4.08% |
| 2015 Q3 | 29 Million USD | -7.38% |
| 2015 FY | 122.22 Million USD | 6.52% |
| 2014 Q4 | 30.55 Million USD | -2.26% |
| 2014 FY | 114.74 Million USD | 69.28% |
| 2014 Q3 | 31.26 Million USD | 4.1% |
| 2014 Q2 | 30.02 Million USD | 31.11% |
| 2014 Q1 | 22.9 Million USD | 22.17% |
| 2013 FY | 67.78 Million USD | 23.07% |
| 2013 Q4 | 18.74 Million USD | 9.63% |
| 2013 Q3 | 17.1 Million USD | 3.06% |
| 2013 Q2 | 16.59 Million USD | 8.15% |
| 2013 Q1 | 15.34 Million USD | 3.55% |
| 2012 Q4 | 14.81 Million USD | 12.48% |
| 2012 Q2 | 13.4 Million USD | -2.0% |
| 2012 Q3 | 13.17 Million USD | -1.75% |
| 2012 Q1 | 13.68 Million USD | 14.33% |
| 2012 FY | 55.08 Million USD | 21.75% |
| 2011 FY | 45.24 Million USD | 23.77% |
| 2011 Q3 | 11.34 Million USD | 0.72% |
| 2011 Q1 | 10.66 Million USD | 21.39% |
| 2011 Q4 | 11.96 Million USD | 5.47% |
| 2011 Q2 | 11.26 Million USD | 5.66% |
| 2010 Q4 | 8.78 Million USD | -3.6% |
| 2010 Q3 | 9.11 Million USD | -2.55% |
| 2010 Q2 | 9.34 Million USD | 0.43% |
| 2010 Q1 | 9.3 Million USD | 11.78% |
| 2010 FY | 36.55 Million USD | 14.36% |
| 2009 Q4 | 8.32 Million USD | 0.0% |
| 2009 FY | 31.96 Million USD | -12.49% |
| 2008 FY | 36.52 Million USD | 33.86% |
| 2007 FY | 27.28 Million USD | 7.9% |
| 2006 FY | 25.28 Million USD | 0.0% |
| 2001 Q3 | 34.78 Million USD | 0.0% |
| 2001 FY | 144.72 Million USD | 0.0% |
| 2001 Q4 | 33.92 Million USD | -2.47% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 23.829% |
| Prenetics Global Limited | 60.73 Million USD | -86.854% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -597.45% |
| CareDx, Inc | 277.76 Million USD | 59.143% |
| Exact Sciences Corporation | 2.06 Billion USD | 94.492% |
| Exagen Inc. | 52.29 Million USD | -117.025% |
| Inotiv, Inc. | 246.9 Million USD | 54.035% |
| Guardant Health, Inc. | 901.62 Million USD | 87.413% |
| Biodesix, Inc. | 77.41 Million USD | -46.591% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -2792.85% |
| Precipio, Inc. | 13.63 Million USD | -732.153% |
| iSpecimen Inc. | 16.27 Million USD | -597.224% |
| Natera, Inc. | 938.98 Million USD | 87.914% |
| Aspira Women's Health Inc. | 24.11 Million USD | -370.635% |
| 23andMe Holding Co. | 420.73 Million USD | 73.026% |
| Castle Biosciences, Inc. | 242.78 Million USD | 53.255% |
| Personalis, Inc. | 128.14 Million USD | 11.436% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -2.682% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -588.366% |
| OpGen, Inc. | 30.65 Million USD | -270.178% |
| T2 Biosystems, Inc. | 41.49 Million USD | -173.507% |
| Myriad Genetics, Inc. | 600.1 Million USD | 81.088% |
| ICON Public Limited Company | 755.64 Million USD | 84.981% |
| NeoGenomics, Inc. | 341.25 Million USD | 66.743% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -597.45% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 89.615% |
| RadNet, Inc. | 268.87 Million USD | 57.792% |
| MDxHealth SA | 71.25 Million USD | -59.269% |
| Psychemedics Corporation | 11.33 Million USD | -901.315% |
| Illumina, Inc. | 3.81 Billion USD | 97.024% |
| Check-Cap Ltd. | 19.28 Million USD | -488.422% |
| Twist Bioscience Corporation | 354.18 Million USD | 67.957% |
| DarioHealth Corp. | 62.17 Million USD | -82.537% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 33.982% |
| Sera Prognostics, Inc. | 39.91 Million USD | -184.312% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -978.717% |
| OPKO Health, Inc. | 574.68 Million USD | 80.252% |
| Medpace Holdings, Inc. | 187.68 Million USD | 39.531% |
| Neogen Corporation | 405.23 Million USD | 71.994% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -869.262% |
| Prenetics Global Limited | 60.73 Million USD | -86.854% |
| Mainz Biomed B.V. | 27.15 Million USD | -317.941% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -1194.821% |
| Trinity Biotech plc | 46.49 Million USD | -144.089% |
| Neuronetics, Inc. | 82.25 Million USD | -37.965% |
| Sotera Health Company | 300.46 Million USD | 62.229% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -1194.821% |